Clinical Scorecard: More Good Than Harm

At a Glance

Key Highlights

• Durysta and iDose TR are FDA-approved sustained-release implants for glaucoma management.
• Durysta lasts 3-12 months; iDose TR lasts 1-2 years.
• Procedural interventions can enhance patient quality of life and reduce medication burden.
• Efficient delivery of implants minimizes disruption to clinic flow.
• Collaboration with billing specialists can ease administrative burdens.

Guideline-Based Recommendations

Diagnosis

• Assess patient history including IOP levels, medication adherence, and previous treatments.

Management

• Consider sustained-release implants for patients with above-target IOP or difficulties with topical medications.

Monitoring & Follow-up

• Schedule follow-up visits a few days to weeks post-implantation to assess outcomes.

Risks

• Potential complications related to implantation and patient-specific factors affecting adherence.

Patient & Prescribing Data

Patients with open-angle glaucoma or ocular hypertension, including those with prior surgical history.

Sustained-release implants can significantly reduce the need for topical medications and improve adherence.

Clinical Best Practices

• Educate all staff involved in the procedure to ensure smooth patient flow.
• Document reasons for recommending sustained-release implants thoroughly.
• Schedule surgical procedures promptly to facilitate timely treatment.

References

• Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant
• Phase 3, Randomized, 20-Month Study of Bimatoprost Implant